(Q42981494)

English

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

scientific article published on 18 June 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

Christophe Hézode

7

object named as

Christophe Hézode

0 references

Megan Wind-Rotolo

20

object named as

Megan Wind-Rotolo

0 references

1

object named as

Stanislas Pol

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Reem H Ghalib

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Vinod K Rustgi

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Claudia Martorell

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Greg T Everson

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Harvey A Tatum

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Christophe Hézode

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Joseph K Lim

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Jean-Pierre Bronowicki

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Gary A Abrams

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Norbert Bräu

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

David W Morris

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Paul J Thuluvath

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Robert W Reindollar

14

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Philip D Yin

15

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ulysses Diva

16

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Robert Hindes

17

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Fiona McPhee

18

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Dennis Hernandez

19

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Megan Wind-Rotolo

20

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Eric A Hughes

21

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Steven Schnittman

22

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

18 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Lancet Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

671-677

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

An overview of emerging therapies for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A review of the treatment of chronic hepatitis C virus infection in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification of Hepatitis C Virus (HCV) RNA in a Multicenter Study: Implications for Management of HCV Genotype 1-Infected Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970138-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(12)70138-X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42981494&oldid=1975636873"